MA55206A - Polyribonucléotides circulaires et compositions pharmaceutiques associées - Google Patents

Polyribonucléotides circulaires et compositions pharmaceutiques associées

Info

Publication number
MA55206A
MA55206A MA055206A MA55206A MA55206A MA 55206 A MA55206 A MA 55206A MA 055206 A MA055206 A MA 055206A MA 55206 A MA55206 A MA 55206A MA 55206 A MA55206 A MA 55206A
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
related pharmaceutical
circular polyribonucleotides
polyribonucleotides
circular
Prior art date
Application number
MA055206A
Other languages
English (en)
Inventor
Catherine Cifuentes-Rojas
Boer Alexandra Sophie De
Avak Kahvejian
Michael Donato Melfi
Ki Young Paek
Nicholas Mccartney Plugis
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MA55206A publication Critical patent/MA55206A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055206A 2019-03-04 2020-03-04 Polyribonucléotides circulaires et compositions pharmaceutiques associées MA55206A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962813666P 2019-03-04 2019-03-04
US201962825683P 2019-03-28 2019-03-28
US201962840174P 2019-04-29 2019-04-29
US202062967545P 2020-01-29 2020-01-29

Publications (1)

Publication Number Publication Date
MA55206A true MA55206A (fr) 2022-01-12

Family

ID=70110338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055206A MA55206A (fr) 2019-03-04 2020-03-04 Polyribonucléotides circulaires et compositions pharmaceutiques associées

Country Status (10)

Country Link
US (1) US20220143062A1 (fr)
EP (1) EP3935162A1 (fr)
JP (2) JP2022523794A (fr)
KR (1) KR20210135265A (fr)
CN (3) CN121081490A (fr)
AU (1) AU2020233404A1 (fr)
CA (1) CA3128626A1 (fr)
IL (1) IL285906A (fr)
MA (1) MA55206A (fr)
WO (1) WO2020181013A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017222911A1 (fr) 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Arn circulaires et leur utilisation dans l'immunomodulation
CN111819185A (zh) 2017-12-15 2020-10-23 旗舰创业创新第六有限责任公司 包含环状多核糖核苷酸的组合物及其用途
WO2020198403A2 (fr) 2019-03-25 2020-10-01 Flagship Pioneering Innovations Vi, Llc Compositions comprenant des polyribonucléotides circulaires modifiés et utilisations associées
CA3203975A1 (fr) 2020-12-03 2022-06-09 Battelle Memorial Institute Compositions de nanoparticules polymeres et de nanostructures d'adn et procedes d'administration non virale
US20240299520A1 (en) * 2021-02-09 2024-09-12 Virginia Commonwealth University Mini circular rna therapeutics and vaccines and methods of use thereof
EP4314281A1 (fr) * 2021-03-26 2024-02-07 Flagship Pioneering Innovations VII, LLC Production de polyribonucléotides circulaires dans un système eucaryote
WO2022204460A1 (fr) * 2021-03-26 2022-09-29 Flagship Pioneering Innovations Vii, Llc Compositions et procédés de production de polyribonucléotides circulaires
EP4314289A1 (fr) * 2021-03-26 2024-02-07 Flagship Pioneering Innovations VII, LLC Production de polyribonucléotides circulaires dans un système procaryote
CA3216359A1 (fr) 2021-04-07 2022-10-13 Battelle Memorial Institute Technologies de conception, de construction, de test et d'apprentissage rapides pour identifier et utiliser des vecteurs non viraux
US20240240219A1 (en) * 2021-05-18 2024-07-18 Flagship Pioneering Innovations Vi, Llc Methods of enriching for circular polyribonucleotides
US20240240218A1 (en) * 2021-05-18 2024-07-18 Flagship Pioneering Innovations Vi, Llc Methods of enriching for circular polyribonucleotides
US20250002898A1 (en) 2021-07-27 2025-01-02 Flagship Pioneering Innovations Vi, Llc Devices, systems and methods for processing
MX2024003262A (es) * 2021-09-17 2024-06-19 Flagship Pioneering Innovations Vi Llc Composiciones y metodos para producir poliribonucleotidos circulares.
EP4422698A1 (fr) * 2021-10-29 2024-09-04 CureVac SE Arn circulaire amélioré pour exprimer des protéines thérapeutiques
KR102488280B1 (ko) * 2021-11-25 2023-01-16 주식회사 뉴클릭스바이오 신규한 부목 dna 및 이의 용도
CN114317684B (zh) * 2021-12-15 2023-12-26 南京大学 一种基于tna分子的细胞内镁离子成像的方法
KR20240118174A (ko) 2021-12-17 2024-08-02 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
WO2023143541A1 (fr) * 2022-01-28 2023-08-03 Beijing Changping Laboratory Vaccins à arn circulaire et leurs procédés d'utilisation
EP4612296A1 (fr) * 2022-10-31 2025-09-10 Flagship Pioneering Innovations VI, LLC Compositions et procédés de purification de polyribonucléotides
WO2024151583A2 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccins et procédés associés
CN121057577A (zh) 2023-01-27 2025-12-02 赛欧生物医药股份有限公司 经修饰的脂质组合物及其用途
WO2024167885A1 (fr) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Compositions immunomodulatrices et procédés associés
CN116286916B (zh) * 2023-02-24 2025-08-22 北京大学人民医院 一种改良的i型内含子核酶序列用于构建环状rna的方法及应用
TW202517783A (zh) * 2023-06-28 2025-05-01 香港商瑞毅生物科技（香港）有限公司 工程化的rna多核苷酸及其製備方法
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025087301A1 (fr) * 2023-10-24 2025-05-01 Therorna Shanghai Co., Ltd. Arn circulaire codant pour glp-1 et son utilisation
WO2025106930A1 (fr) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Polyribonucléotides circulaires codant le peptide 2 de type glucagon (glp-2) et leurs utilisations
WO2025106915A1 (fr) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Polyribonucléotides circulaires codant le peptide 1 de type glucagon (glp-1) et leurs utilisations
WO2025122954A1 (fr) 2023-12-08 2025-06-12 Battelle Memorial Institute Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires
TW202545974A (zh) 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025179198A1 (fr) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Polyribonucléotides circulaires et arn linéaires non modifiés à immunogénicité réduite
WO2025227064A1 (fr) * 2024-04-26 2025-10-30 Renasci Biotechnologies, Inc. Méthodes d'édition génomique pour le traitement d'une maladie cardiovasculaire et compositions destinées à être utilisées dans la mise en œuvre de celles-ci
WO2025240369A2 (fr) * 2024-05-13 2025-11-20 Helix Nanotechnologies Inc Procédés de distribution de polyribonucléotides nus
US20250353881A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (fr) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Protéines de ciblage d'immunorécepteurs et procédés associés
CN118581085A (zh) * 2024-05-24 2024-09-03 国家纳米科学中心 一种翻译调控元件、表达载体、药物组合物、疫苗组合物、构建方法、表达目的蛋白的方法及应用
CN118688370B (zh) * 2024-08-27 2024-12-13 天津辰欣药物研究有限公司 一种抗病毒新药中间体的质量控制方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649066B2 (en) 1990-07-25 1994-05-12 Syngene, Inc. Circular extension for generating multiple nucleic acid complements
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
JPH07502898A (ja) 1992-01-13 1995-03-30 デューク・ユニバーシティー 酵素ｒｎａ分子
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
EP2447370B1 (fr) 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Molécules de micro ARN
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
WO2010084371A1 (fr) 2009-01-26 2010-07-29 Mitoprod Nouvelles molécules d'arn interférent circulaire
WO2011097480A1 (fr) 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Compositions exosomales et procédés pour le traitement de maladies
WO2013070324A1 (fr) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Compositions de microvésicules dérivées de plante comestible pour le diagnostic et le traitement d'une maladie
CA2930665A1 (fr) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Complexes membrane synthetique- recepteur
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
US10407683B2 (en) * 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US20180135012A1 (en) 2015-05-13 2018-05-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP4219532A3 (fr) 2015-06-05 2023-08-16 Dana-Farber Cancer Institute, Inc. Compositions et procédés pour une thérapie génique transitoire à stabilité améliorée
AU2016288643A1 (en) 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
SI3402491T1 (sl) 2016-01-11 2022-05-31 Rubius Therapeutics, Inc. Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
US20180153989A1 (en) 2016-12-02 2018-06-07 Rubius Therapeutics, Inc. Compositions and methods related to cell systems for penetrating solid tumors
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
CA3062426A1 (fr) 2017-05-08 2018-11-15 Flagship Pioneering Innovations V, Inc. Compositions pour faciliter la fusion membranaire et leurs utilisations
CN111819185A (zh) * 2017-12-15 2020-10-23 旗舰创业创新第六有限责任公司 包含环状多核糖核苷酸的组合物及其用途
AR116016A1 (es) 2018-08-24 2021-03-25 Flagship Pioneering Innovations Vi Llc Métodos para fabricar paquetes mensajeros vegetales

Also Published As

Publication number Publication date
CN121081490A (zh) 2025-12-09
US20220143062A1 (en) 2022-05-12
WO2020181013A1 (fr) 2020-09-10
AU2020233404A1 (en) 2021-09-16
CN121081491A (zh) 2025-12-09
EP3935162A1 (fr) 2022-01-12
JP2022523794A (ja) 2022-04-26
CN113544269A (zh) 2021-10-22
IL285906A (en) 2021-10-31
JP2025090772A (ja) 2025-06-17
KR20210135265A (ko) 2021-11-12
CA3128626A1 (fr) 2020-09-10

Similar Documents

Publication Publication Date Title
MA55206A (fr) Polyribonucléotides circulaires et compositions pharmaceutiques associées
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3891149A4 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associées
EP3891148A4 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associées
EP3565550A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3621621A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3436482A4 (fr) Anticorps, compositions pharmaceutiques et procédés
EP3500255A4 (fr) Compositions pharmaceutiques ophtalmiques et utilisations associées
EP3426348A4 (fr) Dérivé de 3-désoxy et compositions pharmaceutiques associées
EP3603620A4 (fr) Composition de liposome et composition pharmaceutique
MA46867A (fr) Formulations pharmaceutiques
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
MA55015A (fr) Formulations pharmaceutiques
EP3914234A4 (fr) Compositions pharmaceutiques
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
EP3773654A4 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
MA47516A (fr) Composition pharmaceutique
MA49837A (fr) Compositions pharmaceutiques
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
DK3908321T3 (da) Farmaceutisk sammensætning
EP3646867A4 (fr) Composition pharmaceutique
EP3646863A4 (fr) Composition pharmaceutique
EP3849523A4 (fr) Compositions pharmaceutiques ophtalmiques à libération prolongée et utilisations associées